Listing 1 - 10 of 124 << page
of 13
>>
Sort by

Book
Rapport sur la santé dans le monde 2004 : changer le cours de l'histoire
Author:
ISBN: 9242562653 Year: 2004 Publisher: Genève Organisation mondiale de la santé

Health care spending in the new EU member states : controlling costs and improving quality
Author:
ISBN: 1280940352 9786610940356 0821371525 0821371517 Year: 2007 Publisher: Washington, D.C. : World Bank,

Loading...
Export citation

Choose an application

Bookmark

Abstract

Following the transition from central planning toward market-based economies, the formerly communist states of Central and Eastern Europe introduced a number of reforms in the finance, management, and organization of the health sector. While health sector reforms in these countries have involved deep structural changes, they have generally been less successful in improving efficiency, enhancing equity in healthcare financing and delivery, and managing clinical quality of health services. Total health expenditures have increased in almost all countries, especially in recent years, and with reve


Book
Financing health care in East Asia and the Pacific : best practices and remaining challenges
Authors: --- ---
ISBN: 0821387367 0821386824 Year: 2011 Publisher: Washington, D.C. : World Bank,

Loading...
Export citation

Choose an application

Bookmark

Abstract

The East Asia and Pacific region is characterized by wide variations in sources of healthcarefinancing, pooling of funds, purchasing of care services, and the extent to which thesepolicy instruments and programs provide social protection. Existing healthcare financingsystems in the region are under increasing pressure from a continued prevalence ofcommunicable diseases, an emergence of non communicable diseases, and a rapidlyaging population.Large inequalities between the poor and the prosperous in their access to healthcarefinancing mechanisms can be reformed and strengthened to improve outco


Book
Paths to sustainability for innovative delivery system programs
Authors: --- ---
ISBN: 9780833091277 0833091271 Year: 2015 Publisher: [Santa Monica, Calif.] Rand Corporation


Book
Organization and financing of public health services in Europe
Authors: ---
ISBN: 9240699023 Year: 2018 Publisher: Copenhagen, Denmark : European Observatory on Health Systems and Policies,

Loading...
Export citation

Choose an application

Bookmark

Abstract


Book
Een beter Nederland : de gouden eieren van de gezondheidszorg.
Author:
ISBN: 9789460032455 Year: 2010 Publisher: Amsterdam Balans

Assessing the economic value of anti-cancer therapies
Author:
ISSN: 00800015 ISBN: 3540640304 3642721257 3642721230 9783540640301 Year: 1998 Volume: 148 Publisher: New York ; Berlin ; Tokyo Springer

Loading...
Export citation

Choose an application

Bookmark

Abstract

BOOK REVIEW Kevin B. Knopf, JNCI, 1999, 91(14), 1248-1249The need for accurate economic analysis to guide health care delivery is irrefutable, since health care costs continue to rise in parallel with a growing demand in value for our spending. Cancer care accounts for 5%-10% of all health care dollars spent in the United States, and although breakthroughs in cancer research will provide much needed improvements in the treatment of cancer, they will also come at a cost. Dr. Neymark speaks in his preface of the "aura of sanctity" surrounding cancer so that "everything possible" is done for the patients. This aura derives partly from the seriousness of the disease and the fear surrounding a diagnosis of cancer. However, a need for high-quality economic research in cancer care is still necessary to guide rational resource allocation, and this text succeeds in succinctly and thoughtfully summarizing the state of the art of economic analysis of cancer therapies. By exploring the literature related to economic evaluation of cancer therapies over a 10-year period, Dr. Neymark has provided a great deal of food for thought for research in this area. The general nature of economic evaluation is defined in the introduction: "Economic evaluation is a widely applicable economic method concerned with the comparison of two or more alternatives with respect to both their positive and negative impacts or benefits and costs, respectively, as these impacts are generally termed. It is the presence of alternative methods of treatments that create an economic problem." It is the presence of choices that makes economic evaluation a valuable tool. In the past, the treatment of cancer, particularly metastatic disease, was limited in the number of options available, as the author notes. However, new treatments are continually being developed, which come with a cost versus benefit trade-off, and thus economic evaluations will assume a greater importance as our therapeutic choices increase. The very brief chapter on the epidemiology of cancer could have been made more substantial, and the addition of graphs to interpret trends would have been useful. The following chapter provides an excellent overview of the nature of cancer and its major treatment modalities, which will be of interest to the nonclinician. The chapters on economic evaluation and the economic burden of cancer are well written and serve as solid introductions for the novice to these areas and a good review for others. He describes the rationale and methods behind the cost-of-illness studies, which he treats with a healthy skepticism. A lengthy section on economic evaluation covers important concepts and describes, in turn, the four major types of studies: cost-minimization, cost-benefit, cost-effectiveness, and cost-utility, the latter two being the most appropriate type of study for most cancer therapeutics. Discussion about methodology involved in collecting data for cost and outcomes, perspective of the analysis, valuation, and presentation and interpretation of results of economic evaluations are also well written. The heart of the text is a thorough discussion of the major economic studies of cancer treatment published from 1985 to 1996. The author reviews the relevant literature pertaining to costs and treatment of most of the major malignancies, including relevant supportive care areas. Topics covered include the following: breast cancer (14 studies), lung cancers (eight studies), colorectal cancer (eight studies), prostate cancer (10 studies), genitourinary and gynecologic malignancies (11 studies), leukemias and lymphomas (10 studies), therapies for emesis and infections (nine studies), hematologic support and transplantation (18 studies), and palliative care (five studies). Every section is preceded by an overview of treatment options that are fairly accurate—although not without occasional omissions and errors; these sections will be invaluable for the nonclinician. Each study is described concisely, including rationale, type of analysis, perspective, techniques, data sources, and results, when stated by the original authors. Dr. Neymark justly criticizes studies with conceptual or methodologic flaws, erroneous assumptions, or clear oversights in the evaluation, and as a critical reviewer, he certainly holds no punches. This lengthy and in-depth review of a body of work makes his text a compelling read and enables the reader to gain a great deal of insight into how to, and often how not to, evaluate the economics of cancer therapeutics. Through reading his summation of the body of literature, one obtains an appreciation of not only what studies have been performed and which studies should be performed but also a sense of the "state of the art of the methodology" currently in use. Each chapter closes with a concise table of the articles reviewed and concluding comments that highlight the strengths and weaknesses in the studies, comparing studies when appropriate, and pointing out possible future directions. A concluding chapter discusses some of the broader controversies, which have been hinted at throughout the review, in an insightful manner. The use of "league tables" to compare cost-effectiveness ratios is justly criticized, due to the implicit assumption of comparability of studies. The issue of costs versus charges is briefly discussed, and a lengthy discussion of the merits of collecting economic data in clinical trials points to the complementary benefit of modeling. The nature of outcomes used, e.g., the inapplicability of life-years saved as an outcome to evaluate antiemetic therapies, is also explored. By design, this review cannot serve as a complete "how to" guide for economic evaluations, although there are many pearls to be gained from a thorough reading. The economics of cancer prevention and screening, which are in many ways more difficult to study from an economic perspective, were not explored in this text, but there are other sources for this information. Many of the reviewed studies are excellent and may serve as an aide to treatment choices for a specific situation. In a broader sense, this book will be extremely valuable for both the health service researcher who wishes to learn about cancer economics and the cancer researcher interested in the economic aspects of their field. By reviewing 9 years of the literature in a systematic, thoughtful, and critical manner, there is much to be gained for the interested reader who invests a small amount of time reading this excellent work.


Book

Book
Rapport sur la santé dans le monde : 2001 : la santé mentale : nouvelle conception, nouveaux espoirs
Author:
ISBN: 9242562017 Year: 2001 Publisher: Genève Organisation mondiale de la santé


Book
Rapport sur la santé dans le monde 2000 : pour un système de santé plus performant.
Author:
ISBN: 9242561983 Year: 2000 Publisher: Genève : OMS [Organisation Mondiale de la Santé] = WHO [World Health Organization],

Listing 1 - 10 of 124 << page
of 13
>>
Sort by